Olopatadine HCL 0. 1% Ophthalmic Solution
Awarded Award Notice Posted
- Solicitation number
- SPE2D222R0117
- Agency
- Medical Supply Chain Troop Support, Department of Defense
- Awarded
- to Golden State Medical Supply, Inc.
- Set-aside
- No set-aside
Opportunity facts
- Contract number
- SPE2D223D0007 Federal IDV award
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Place of performance
- Ontario Canada Canada
- Points of contact
-
- Kyle Lewicki kyle.lewicki@dla.mil (445) 737-0977
- Jason Wray jason.wray@dla.mil (445) 737-6304
Notice details come from SAM.gov. Updated .
About this opportunity
The Defense Logistics Agency Troop Support Medical Supply Chain awarded contract SPE2D2-23-D-0007 to Golden State Medical Supply Inc. for $17.621 million covering Olopatadine HCL 0.1% Ophthalmic Solution 5ML bottles on February 15, 2023.
The contract was structured with a base period and three one-year option periods exercised through February 14, 2027. Contractor location is Camarillo, California. The contract has been terminated for convenience effective September 24, 2026, through a no-cost bilateral settlement (Modification P00013).
Over the contract lifecycle, several significant modifications were issued: Modification P00011 (effective June 1, 2026) changed the manufacturer and place of performance from Apotex Inc. to SamChunDang Pharm Co., Ltd., a contracted manufacturing organization for Glenmark Therapeutics Inc., USA, located in Gwaseong, South Korea, while introducing a new National Drug Code (51407-0938-05) alongside the existing NDC (51407-0663-05) at a unit price of $10.16 per bottle. Modifications also incorporated FAR compliance clauses including Drug Supply Chain Security Act language (P00003), ByteDance Covered Application prohibitions (P00002), Federal Acquisition Supply Chain Security Act Orders (P00005), and DEI discrimination clauses (P00012), alongside DoD Class Deviation 2025-O0003 eliminating certain environmental and EEO reporting requirements (P00007).
Notice text
8 versions
Update #8 · Latest ·
Modification SPE2D223D0007 P00013 No-Cost Settlement Termination for Convenience.
Modification SPE2D223D0007 P00012 is issued to incorporate clause 52.222-90, Addressing DEI Discrimination by Federal Contractors (DEVIATION 2026-O0040, REVISION 1) (APR 2026).
Modification SPE2D223D0007 P00011 to change the Manufacturer, Place of Performance and NDC for Olopatadine HCL 0.1% Ophthalmic Solution 5ML Bottle.
Modification SPE2D223D0007 P00010 to update new POC for Golden State Medical Supply, Inc. cage code 1HT23.
Modification SPE2D223D0007 P00008 to exercise Option Year 3 effective February 15, 2026 through February 14, 2027.
Modification SPE2D223D0007 P00007 is modified in accordance with DoD Class Deviation 2025-O0003.
Modification SPE2D223D0007 P00006 to exercise Option Year 2 effective February 15, 2025 through February 14, 2026.
Modification SPE2D223D0007 P00005 to incorporate FAR 52.204-30 Federal Acquisition Supply Chain Security Act Orders language into solicitation for subject contract.
Modification SPE2D223D0007 P00004 to exercise Option Year 1 effective February 15, 2024 through February 14, 2025.
Modification SPE2D223D0007 P00003 to incorporate Drug Supply Chain Security Act language into solicitation for subject contract.
Modification SPE2D223D0007 P00002 to incorporate clause FAR 52.204-27 Prohibition on a ByteDance Covered Application (JUN 2023) into subject contract.
Modification P00001 SPE2D2-23-D-0007 revising the the price effective date and ship date from April 16, 2023 to February 28, 2023.
Contract Award for Olopatadine HCL 0.1% Opthtalmic Solution 5ML Bottle
Awarded contract SPE2D223D0007 to GOLDEN STATE MEDICAL SUPPLY INC for 17621453.20 on 2023-02-15.
Update #7 ·
Modification SPE2D223D0007 P00011 to change the Manufacturer, Place of Performance and NDC for Olopatadine HCL 0.1% Ophthalmic Solution 5ML Bottle.
Modification SPE2D223D0007 P00010 to update new POC for Golden State Medical Supply, Inc. cage code 1HT23.
Modification SPE2D223D0007 P00008 to exercise Option Year 3 effective February 15, 2026 through February 14, 2027.
Modification SPE2D223D0007 P00007 is modified in accordance with DoD Class Deviation 2025-O0003.
Modification SPE2D223D0007 P00006 to exercise Option Year 2 effective February 15, 2025 through February 14, 2026.
Modification SPE2D223D0007 P00005 to incorporate FAR 52.204-30 Federal Acquisition Supply Chain Security Act Orders language into solicitation for subject contract.
Modification SPE2D223D0007 P00004 to exercise Option Year 1 effective February 15, 2024 through February 14, 2025.
Modification SPE2D223D0007 P00003 to incorporate Drug Supply Chain Security Act language into solicitation for subject contract.
Modification SPE2D223D0007 P00002 to incorporate clause FAR 52.204-27 Prohibition on a ByteDance Covered Application (JUN 2023) into subject contract.
Modification P00001 SPE2D2-23-D-0007 revising the the price effective date and ship date from April 16, 2023 to February 28, 2023.
Contract Award for Olopatadine HCL 0.1% Opthtalmic Solution 5ML Bottle
Awarded contract SPE2D223D0007 to GOLDEN STATE MEDICAL SUPPLY INC for 17621453.20 on 2023-02-15.
Update #6 ·
Modification SPE2D223D0007 P00008 to exercise Option Year 3 effective February 15, 2026 through February 14, 2027.
Modification SPE2D223D0007 P00007 is modified in accordance with DoD Class Deviation 2025-O0003.
Modification SPE2D223D0007 P00006 to exercise Option Year 2 effective February 15, 2025 through February 14, 2026.
Modification SPE2D223D0007 P00005 to incorporate FAR 52.204-30 Federal Acquisition Supply Chain Security Act Orders language into solicitation for subject contract.
Modification SPE2D223D0007 P00004 to exercise Option Year 1 effective February 15, 2024 through February 14, 2025.
Modification SPE2D223D0007 P00003 to incorporate Drug Supply Chain Security Act language into solicitation for subject contract.
Modification SPE2D223D0007 P00002 to incorporate clause FAR 52.204-27 Prohibition on a ByteDance Covered Application (JUN 2023) into subject contract.
Modification P00001 SPE2D2-23-D-0007 revising the the price effective date and ship date from April 16, 2023 to February 28, 2023.
Contract Award for Olopatadine HCL 0.1% Opthtalmic Solution 5ML Bottle
Awarded contract SPE2D223D0007 to GOLDEN STATE MEDICAL SUPPLY INC for 17621453.20 on 2023-02-15.
Update #5 ·
Modification SPE2D223D0007 P00006 to exercise Option Year 2 effective February 15, 2025 through February 14, 2026.
Modification SPE2D223D0007 P00005 to incorporate FAR 52.204-30 Federal Acquisition Supply Chain Security Act Orders language into solicitation for subject contract.
Modification SPE2D223D0007 P00004 to exercise Option Year 1 effective February 15, 2024 through February 14, 2025.
Modification SPE2D223D0007 P00003 to incorporate Drug Supply Chain Security Act language into solicitation for subject contract.
Modification SPE2D223D0007 P00002 to incorporate clause FAR 52.204-27 Prohibition on a ByteDance Covered Application (JUN 2023) into subject contract.
Modification P00001 SPE2D2-23-D-0007 revising the the price effective date and ship date from April 16, 2023 to February 28, 2023.
Contract Award for Olopatadine HCL 0.1% Opthtalmic Solution 5ML Bottle
Awarded contract SPE2D223D0007 to GOLDEN STATE MEDICAL SUPPLY INC for 17621453.20 on 2023-02-15.
Update #4 ·
Modification SPE2D223D0007 P00004 to exercise Option Year 1 effective February 15, 2024 through February 14, 2025.
Modification SPE2D223D0007 P00003 to incorporate Drug Supply Chain Security Act language into solicitation for subject contract.
Modification SPE2D223D0007 P00002 to incorporate clause FAR 52.204-27 Prohibition on a ByteDance Covered Application (JUN 2023) into subject contract.
Modification P00001 SPE2D2-23-D-0007 revising the the price effective date and ship date from April 16, 2023 to February 28, 2023.
Contract Award for Olopatadine HCL 0.1% Opthtalmic Solution 5ML Bottle
Awarded contract SPE2D223D0007 to GOLDEN STATE MEDICAL SUPPLY INC for 17621453.20 on 2023-02-15.
Update #3 ·
Modification SPE2D223D0007 P00003 to incorporate Drug Supply Chain Security Act language into solicitation for subject contract.
Modification SPE2D223D0007 P00002 to incorporate clause FAR 52.204-27 Prohibition on a ByteDance Covered Application (JUN 2023) into subject contract.
Modification P00001 SPE2D2-23-D-0007 revising the the price effective date and ship date from April 16, 2023 to February 28, 2023.
Contract Award for Olopatadine HCL 0.1% Opthtalmic Solution 5ML Bottle
Awarded contract SPE2D223D0007 to GOLDEN STATE MEDICAL SUPPLY INC for 17621453.20 on 2023-02-15.
Update #2 ·
Modification P00001 SPE2D2-23-D-0007 revising the the price effective date and ship date from April 16, 2023 to February 28, 2023.
Contract Award for Olopatadine HCL 0.1% Opthtalmic Solution 5ML Bottle
Awarded contract SPE2D223D0007 to GOLDEN STATE MEDICAL SUPPLY INC for 17621453.20 on 2023-02-15.
Update #1 ·
Contract Award for Olopatadine HCL 0.1% Opthtalmic Solution 5ML Bottle
Awarded contract SPE2D223D0007 to GOLDEN STATE MEDICAL SUPPLY INC for 17621453.20 on 2023-02-15.
Attachments
Show all 13
Notice history
| Notice | Type | Posted |
|---|---|---|
| Olopatadine HCL 0. 1% Ophthalmic Solution | Award Notice | |
| Pharm Manuf/Distr Div - FSA | Award Notice | |
| Olopatadine HCL 0. 1% Ophthalmic Solution | Solicitation | |
| Olopatadine HCL 0. 1% Ophthalmic Solution | Pre-Solicitation |
On GovTribe
Work this opportunity on GovTribe
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity